Phase II open‐label multicenter study to assess the antitumor activity of afatinib in lung cancer patients with activating epidermal growth factor receptor mutation from circulating tumor DNA: Liquid‐Lung‐A

BACKGROUND: Mutation analysis of circulating tumor DNA (ctDNA) is used for diagnosing lung cancer. This trial aimed to assess the efficacy of afatinib in treatment‐naïve patients with lung cancer harboring epidermal growth factor receptor mutations (EGFRm, exon 19 deletions or exon 21 point mutation...

Descripción completa

Detalles Bibliográficos
Autores principales: Park, Cheol‐Kyu, Lee, Sung‐Yong, Lee, Jae Cheol, Choi, Chang‐Min, Lee, Shin Yup, Jang, Tae‐Won, Oh, In‐Jae, Kim, Young‐Chul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7882376/
https://www.ncbi.nlm.nih.gov/pubmed/33270375
http://dx.doi.org/10.1111/1759-7714.13763

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7882376/
https://www.ncbi.nlm.nih.gov/pubmed/33270375
http://dx.doi.org/10.1111/1759-7714.13763

Ejemplares similares